Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Completed Not applicable Interventional Results available

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

NCT03369067
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

NCT00457392
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
erlotinib, sunitinib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
63
States / cities
Florence, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

NCT03694444
View directory record Official record
Conditions
Gingivitis
Interventions
AMY-101, Water for injection
Drug · Other
Lead sponsor
Amyndas Pharmaceuticals S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 29, 2026, 10:07 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
Risvutatug Rezetecan
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Los Alamitos, California • Los Angeles, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-Human Study of ICT01 in Patients With Advanced Cancer

NCT04243499
View directory record Official record
Conditions
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
Interventions
IV ICT01
Biological
Lead sponsor
ImCheck Therapeutics, an Ipsen company
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Gilbert, Arizona • Duarte, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss

NCT06729632
View directory record Official record
Conditions
Noise Exposure, Noise-induced Hearing Loss, Noise; Adverse Effect, Mild Therapeutic Hypothermia, Cooling, Occupational Exposure, Occupational Health, Hidden Hearing Loss
Interventions
Cold pack-delivered mild therapeutic hypothermia
Device
Lead sponsor
Restorear Devices LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise and Therapeutic Learning Among Women With PTSD

NCT04113798
View directory record Official record
Conditions
PTSD
Interventions
Day 1 Assessments, Day 2 Fear Learning, Day 3 Fear Extinction, Moderate Intensity Exercise, Low Intensity Exercise, Day 4 Recall of Fear Extinction
Other · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 29, 2026, 10:07 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

NCT05947500
View directory record Official record
Conditions
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
50
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Not listed Phase 2 Interventional

Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

NCT02369926
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Multiple Sclerosis Functional Composite, Mobile Multiple Sclerosis Functional Composite
Procedure
Lead sponsor
Transparency Life Sciences
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

NCT04200352
View directory record Official record
Conditions
Cerebral Palsy, Dyskinetic
Interventions
TEV-50717
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Voorhees Township, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional

Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste

NCT02992314
View directory record Official record
Conditions
Medication Associated Metallic Taste , Dysgeusia
Interventions
Metaqil™ Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 29, 2026, 10:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

NCT04865133
View directory record Official record
Conditions
COVID-19 Infection, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 29, 2026, 10:07 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Safety in Ovarian Cancer for Average-Risk Women - Analysis

NCT07872644
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Blood-Based Ovarian Cancer Screening Test
Diagnostic Test
Lead sponsor
Mercy BioAnalytics, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Waltham, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

NCT04510376
View directory record Official record
Conditions
Allergic Reaction
Interventions
Test Article, Positive Control, Negative Control
Device · Other
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03733444
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional Results available

An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma

NCT02591472
View directory record Official record
Conditions
Musculoskeletal Injury Trauma
Interventions
Integrated care (ICare), Usual Care (UsCare), Patient-Reported Outcomes Measurement Information System, Lower Extremity Gain Scale (LEGS), Dynamometer, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11)
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens

NCT05927753
View directory record Official record
Conditions
Refractive Error - Myopia Bilateral
Interventions
Deseyne Daily Disposable Contact Lens (Test Device)
Device
Lead sponsor
Bruno Vision Care
Industry
Eligibility
18 Years to 40 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Longwood, Florida • Pittsburg, Kansas • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 29, 2026, 10:07 PM EDT
Active, not recruiting Phase 2 Interventional

Cevostamab Following CAR T Cell Therapy for RRMM

NCT05801939
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Cevostamab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

NCT04875975
View directory record Official record
Conditions
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions
Rozanolixizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Incorporation of Safe Sleep Education Into m-Health Technology

NCT06074211
View directory record Official record
Conditions
Sudden Infant Death
Interventions
Safety in Seconds mobile app: Safe Sleep Education, Safety in Seconds mobile app: Car Seat Safety Education
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males

NCT00540553
View directory record Official record
Conditions
Healthy Subjects, Androgen Deficiency
Interventions
placebo, GSK971086
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Phase 1 Interventional

Study of Tazemetostat in Lymphoid Malignancies

NCT05983965
View directory record Official record
Conditions
T-cell Lymphoma
Interventions
Tazemetostat
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 2 Interventional Results available

Safety and Dose Finding Study of Xigris in Hemodialysis Patients

NCT01227187
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Drotrecogin alfa activated (Xigris)
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 29, 2026, 10:07 PM EDT